title: Management of neonatal abstinence syndrome from opioids.
abstract: Most infants at risk for neonatal abstinence syndrome have opioid plus another drug exposure; polypharmacy is the rule rather than the exception. Scales for evaluation of neonatal abstinence syndrome are primarily based for opioid withdrawal. A standard protocol to treat neonatal abstinence syndrome has not been developed. Institute nonpharmacologic strategies for all neonates at risk. The American Academy of Pediatrics recommends mechanism-directed therapy (treat opioid withdrawal with an opioid) as the first-line therapy. Second-line medications are currently under evaluation.
authors: Department of Anesthesiology, College of Medicine, Mayo Clinic, 200 First Street, Southwest, Rochester, MN 55902, USA.
authors: Kendra
authors: K
authors: Grim
authors: Tracy E
authors: TE
authors: Harrison
authors: Robert T
authors: RT
authors: Wilder
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000627:therapeutic use; D002047:Buprenorphine / Q000627:therapeutic use; D005248:Feeding Methods; D006801:Humans; D007224:Infant Care / Q000379:methods; D007231:Infant, Newborn; D008691:Methadone / Q000627:therapeutic use; D009020:Morphine / Q000627:therapeutic use; D009357:Neonatal Abstinence Syndrome / Q000628:therapy*; D058850:Opiate Substitution Treatment / Q000379:methods; D041361:Pacifiers; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine; D009020:Morphine; D008691:Methadone
keywords: Abstinence; Buprenorphine; Methadone; Neonatal; Opioids; Withdrawal